Opinion|Videos|February 14, 2025
Final Thoughts on Bispecifics in B-Cell Lymphomas From ASH 2024
Panelists share their final thoughts on bispecific therapies in B-cell lymphomas based on insights from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition 2024.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Thanks to all of you for this rich and informative discussion. Before we conclude, I’d like to get final thoughts from each of you.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Oral COVID-19 PEP May Benefit High-Risk Groups More Than General Public: Peter J. Hotez, MD
2
Hybrid, Outpatient, Network-Based: Bispecific Programs Take Shape Differently
3
5 Ongoing Clinical Trials in Myeloproliferative Neoplasms
4
Defunding Co-Payment Assistance Disrupted nAMD Care
5